The Jean Boulle Group (“the Group”) is pleased to announce a US$47 million cash investment (“the Investment”) in Jean Boulle Medtech’s proprietary VDYNE heart valve technology from a new major strategic investor. The proceeds of the Investment will be used to accelerate human clinical trials of VYDNE’s novel .